Article (Scientific journals)
Cannabinoid-1 receptor antagonists in type-2 diabetes.
Scheen, André
2007In Best Practice and Research. Clinical Endocrinology and Metabolism, 21 (4), p. 535-53
Peer Reviewed verified by ORBi
 

Files


Full Text
Cannabinoid-1 receptor antagonists_ocr.pdf
Author postprint (472.14 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2/drug therapy; Endocannabinoids/physiology; Feeding Behavior/drug effects; Humans; Obesity/drug therapy; Piperidines/therapeutic use; Pyrazoles/therapeutic use; Receptor, Cannabinoid, CB1/antagonists & inhibitors/physiology
Abstract :
[en] Type-2 diabetes is closely related to abdominal obesity and is generally associated with other cardiometabolic risk factors, resulting in a risk of major cardiovascular disease. Several animal and human observations suggest that the endocannabinoid system is over-active in the presence of abdominal obesity and/or diabetes. Both central and peripheral endocannabinoid actions, via the activation of CB1 receptors, promote weight gain and associated metabolic changes. Rimonabant, the first selective CB(1) receptor blocker in clinical use, has been shown to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance index and C-reactive protein levels, and to increase high-density lipoprotein (HDL) cholesterol and adiponectin concentrations in both non-diabetic and diabetic overweight/obese patients. In addition, a 0.5-0.7% reduction in HbA1c levels was observed in metformin- or sulphonylurea-treated patients with type-2 diabetes and in drug-naive diabetic patients. Almost half of the metabolic changes, including HbA1c reduction, could not be explained by weight loss, suggesting that there are direct peripheral effects. Rimonabant was generally well-tolerated, and the safety profile was similar in diabetic and non-diabetic patients, with a higher incidence of depressed mood disorders, nausea and dizziness. In conclusion, the potential role of rimonabant in overweight/obese patients with type-2 diabetes and at high risk of cardiovascular disease deserves much consideration.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
English
Title :
Cannabinoid-1 receptor antagonists in type-2 diabetes.
Publication date :
2007
Journal title :
Best Practice and Research. Clinical Endocrinology and Metabolism
eISSN :
1878-1594
Publisher :
Bailliere Tindall And Cassell, United Kingdom
Volume :
21
Issue :
4
Pages :
535-53
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 16 March 2009

Statistics


Number of views
134 (2 by ULiège)
Number of downloads
596 (0 by ULiège)

Scopus citations®
 
32
Scopus citations®
without self-citations
24
OpenCitations
 
22

Bibliography


Similar publications



Contact ORBi